Bath & Body Works Stock in Brief

Bath & Body Works logged a -0.12% change during today's afternoon session, and is now trading at a price of $42.37 per share. The S&P 500 index moved 0.63% and the Nasdaq posted a 1.02% change.

Bath & Body Works shares moved -20.53% over the last 52 weeks, with a high of $56.96 and a low of $25.34. During this time, the stock lagged the S&P 500 index by -11.3%. As of January 2022, the company's 50-day average price is $44.05. None. The mid-cap Consumer Cyclical company is based in Columbus, OH. Bath & Body Works has returned a 1.84% dividend yield over the last 12 months.

Exceptional EPS Growth Obtained Primarily Through Share Buybacks:

2019-02-02 2020-02-01 2021-01-30 2022-01-29
Revenue (MM) $12,852 $12,496 $11,356 $7,299
Revenue Growth n/a -2.77% -9.12% -35.73%
Gross Margins 38.12% 19.1% 27.26% 52.82%
Gross Margins Growth n/a -49.9% 42.72% 93.76%
Operating Margins 9.62% 8.32% 14.12% 27.52%
Operating Margins Growth n/a -13.51% 69.71% 94.9%
Earnings Per Share $2.34 -$1.32 $3.04 $5.25
EPS Growth n/a -156.41% 330.3% 72.7%
Free Cash Flow (MM) $748 $778 $1,811 $1,222
FCF Growth n/a 4.01% 132.78% -32.52%
Capital Expenditures (MM) $629 $458 $228 $270
Net Debt / EBITDA 2.4 5.16 1.65 1.25

Bath & Body Works Is Fairly Priced at Current Levels:

Compared to the Consumer Cyclical sector's average of 22.33, Bath & Body Works has a trailing twelve month P/E ratio of 12.46 and, according to its EPS guidance of 4.07, an expected P/E ratio of None.

Bath & Body Works's elevated P/B ratio notwithstanding, the company's strong cash flows, decent earnings multiple, and healthy debt levels factor towards it being fairly valued.

18 analysts are following Bath & Body Works and have set target prices ranging from $40.0 to $76.0 per share. On average, they have given the company a rating of buy. At the current price of $42.37, BBWI is trading -18.25% away from its average analyst target price of $51.83 per share, implying an analyst consensus of some upside potential for the stock.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.